EMA — authorised 27 March 2011
- Application: EMEA/H/C/001245
- Marketing authorisation holder: Glaxo Group Limited
- Local brand name: Trobalt
- Indication: Trobalt is indicated as adjunctive treatment of drug-resistant partial-onset seizures with or without secondary generalisation in patients aged 18 years or older with epilepsy, where other appropriate drug combinations have proved inadequate or have not been tolerated.
- Status: withdrawn